OncoSil Medical is Looking Forward to Add Liver Cancer to its Treatment Programs
Published By : 16 Mar 2015 | Published By : QYRESEARCH
OncoSil™ Medical announced that the company has added liver cancer to its development program in order to find the most effective cure of treating pancreatic cancer, after it was revealed by the clinical data set that the OncoSil™ device technology demonstrated the capability of being used against two solid types of tumor. A source from the industry said that new school implantable radiotherapies offered by OncoSil™ will give a ray of hope to cancer sufferers.
According to sources, the company is gearing up to file for the CE Mark in both liver and pancreatic cancer by the second half of 2015. The CE Mark is the compulsory designation that is required by regulators in order to sell OncoSil™ across the European Union, hence it is also an important component that the OncoSil™ must consider in its development pathway.
It has been told that the decision to actively venture in the field of hepatocellular carcinoma or HCC which is commonly known as liver cancer, came as a consequence to the detailed regulatory and clinical review conducted by a team led by the new chief executive officer for OncoSil, Daniel Kenny.
Prior to this, OncoSil has already completed two Pilot Clinical Studies and Trials on the use of localized radiation therapy by OncoSil™ in the treatment of hepatocellular carcinoma. The company believes that the clinical trial would deliver a more important development program in the world of medicine, which will target two of the most dangerous and difficult to treat cancers.
In fact evaluations of safety data with regards to the study revealed that OncoSil™ therapy is easily tolerate-able among patients who are diagnosed with unresectable hepatocellular carcinoma. Moreover, the efficacy data of the clinical trial indicated that OncoSil™ had effected in the significant reduction of the volume of tumors in the liver.